SCHEMBL6489549

SCHEMBL6489549

CCOC(=O)c1ccccc1COc1cc(C)c2nc(C)n(Cc3ccc(C(F)(F)F)cc3F)c2c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MRGPRX4 Q96LA9 3/20 0.44
FFAR1 O14842 1/20 0.39
ALOX5AP P20292 7/20 0.38
MAOB P27338 1/20 0.37
HDAC3 O15379 1/20 0.37
HDAC4 P56524 1/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC7 Q8WUI4 1/20 0.37
HDAC2 Q92769 1/20 0.37
HDAC10 Q969S8 1/20 0.37
HDAC11 Q96DB2 1/20 0.37
HDAC8 Q9BY41 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
HDAC9 Q9UKV0 1/20 0.37
HDAC5 Q9UQL6 1/20 0.37
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
GAA P10253 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6490402 0.91 MRGPRX4 (0.48) MRGPRX4FFAR1ALOX5APOPRL1PIK3CD
SCHEMBL6496808 0.82 PPARG (0.38) FFAR1ALOX5APHDAC3HDAC4HDAC1
SCHEMBL6492596 0.79 GLP1R (0.39) ALOX5APHDAC3HDAC4HDAC1HDAC7
SCHEMBL6491177 0.79 PPARD (0.40) FFAR1ALOX5APHDAC3HDAC4HDAC1
SCHEMBL6490840 0.78 BCL2 (0.46) ALOX5APKDM4EALDH1A1GAAMAPT
SCHEMBL6500775 0.78 MEN1 (0.37) MRGPRX4MEN1KMT2AKDM4EALDH1A1
SCHEMBL6489142 0.77 GLP1R (0.42) ALOX5APHDAC3HDAC4HDAC1HDAC7
SCHEMBL6487299 0.77 MRGPRX4 (0.42) MRGPRX4MEN1KMT2AKDM4EALDH1A1
SCHEMBL6499570 0.76 BCL2 (0.42) ALOX5APMEN1KMT2AMAPT
SCHEMBL6488861 0.75 BCL2 (0.44) MRGPRX4KMT2APIK3CDPIK3C2BPIK3R1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050014812-A1 Benzimidazole compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-01-20 US disclosed
WO-2004108686-A2 BENZIMIDAZOLE COMPOUNDS HAVING HYPOGLYCEMIC ACTIVITY FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014812-A1 Benzimidazole compounds SLC5A1, SLC5A2, G6PD MRGPRX4 2443/4885FFAR1 1226/4885ALOX5AP 4663/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.